'High dose' aprotinin and heparin-coated circuits: Clinical efficacy and inflammatory response

A. Parolari, F. Alamanni, T. Gherli, S. Salis, R. Spirito, F. Foieni, F. Rossi, A. Bertera, P. Oddono, P. Biglioli

Research output: Contribution to journalArticle

Abstract

Heparin-coated cardiopulmonary bypass circuits reduce the inflammatory response to cardiopulmonary bypass circuit, improve biocompatibility and may protect the postoperative hemostasic mechanisms in routine coronary bypass operations. 'High-dose' aprotinin reduces blood-loss, transfusion needs, and re-explorations as a result of bleeding, and may have an additional role in reducing the inflammatory response of the body to cardiopulmonary bypass circuit. It has not been established, however, if the addition of a heparin- coated circuit to the intraoperative administration of 'high dose' aprotinin further reduces the whole-body inflammatory response to cardiopulmonary bypass circuit and improves the postoperative clinical course of the patients who are undergoing coronary surgery. Thirty patients undergoing primary elective coronary artery bypass grafting were studied. All the patients received, intraoperatively, the serine-protease inhibitor aprotinin according to the 'Hammersmith' protocol and full heparin dose. Patients were randomly allocated to be treated either with a circuit completely coated with surface- bound heparin (n = 15) or with an uncoated, but otherwise identical, circuit (n = 15). Differences in the clinical course of the two groups of patients, as well as differences in the behavior of hematological and inflammatory (interleukin-6 (IL-6) and C-reactive protein) factors before, during and after bypass, were analyzed. There were no significant differences between the two groups in terms of bleeding and transfusional requirements, the time spent on a ventilator, or in duration of stay in the intensive care unit (ICU). In all patients, a significant increase in the total white blood cell count, neutrophils, serum IL-6 and C-reactive protein occurred in relation to cardiopulmonary bypass. This was not influenced by heparin precoating of the circuit. In addition, there was an increase in the monocyte count during follow-up, and there was a trend towards higher monocyte counts in the patients who were treated with heparin-coated circuits. These results suggest that the addition of a heparin-coated circuit to the intraoperative 'high- dose' aprotinin therapy probably had little influence on the clinical course and on the time-course of the inflammatory parameters of the adult patients undergoing primary coronary surgery with a full heparinization protocol.

Original languageEnglish
Pages (from-to)117-127
Number of pages11
JournalCardiovascular Surgery
Volume7
Issue number1
DOIs
Publication statusPublished - Jan 1999

Fingerprint

Aprotinin
Heparin
Cardiopulmonary Bypass
C-Reactive Protein
Monocytes
Interleukin-6
Hemorrhage
Serine Proteinase Inhibitors
Mechanical Ventilators
Leukocyte Count
Coronary Artery Bypass
Blood Transfusion
Intensive Care Units
Neutrophils
Serum

Keywords

  • Aprotinin
  • Cardiopulmonary bypass
  • Heparin coated circuits
  • Inflammation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging
  • Surgery

Cite this

'High dose' aprotinin and heparin-coated circuits : Clinical efficacy and inflammatory response. / Parolari, A.; Alamanni, F.; Gherli, T.; Salis, S.; Spirito, R.; Foieni, F.; Rossi, F.; Bertera, A.; Oddono, P.; Biglioli, P.

In: Cardiovascular Surgery, Vol. 7, No. 1, 01.1999, p. 117-127.

Research output: Contribution to journalArticle

Parolari, A. ; Alamanni, F. ; Gherli, T. ; Salis, S. ; Spirito, R. ; Foieni, F. ; Rossi, F. ; Bertera, A. ; Oddono, P. ; Biglioli, P. / 'High dose' aprotinin and heparin-coated circuits : Clinical efficacy and inflammatory response. In: Cardiovascular Surgery. 1999 ; Vol. 7, No. 1. pp. 117-127.
@article{2f63b5aa07594427a101cec42dccc9d0,
title = "'High dose' aprotinin and heparin-coated circuits: Clinical efficacy and inflammatory response",
abstract = "Heparin-coated cardiopulmonary bypass circuits reduce the inflammatory response to cardiopulmonary bypass circuit, improve biocompatibility and may protect the postoperative hemostasic mechanisms in routine coronary bypass operations. 'High-dose' aprotinin reduces blood-loss, transfusion needs, and re-explorations as a result of bleeding, and may have an additional role in reducing the inflammatory response of the body to cardiopulmonary bypass circuit. It has not been established, however, if the addition of a heparin- coated circuit to the intraoperative administration of 'high dose' aprotinin further reduces the whole-body inflammatory response to cardiopulmonary bypass circuit and improves the postoperative clinical course of the patients who are undergoing coronary surgery. Thirty patients undergoing primary elective coronary artery bypass grafting were studied. All the patients received, intraoperatively, the serine-protease inhibitor aprotinin according to the 'Hammersmith' protocol and full heparin dose. Patients were randomly allocated to be treated either with a circuit completely coated with surface- bound heparin (n = 15) or with an uncoated, but otherwise identical, circuit (n = 15). Differences in the clinical course of the two groups of patients, as well as differences in the behavior of hematological and inflammatory (interleukin-6 (IL-6) and C-reactive protein) factors before, during and after bypass, were analyzed. There were no significant differences between the two groups in terms of bleeding and transfusional requirements, the time spent on a ventilator, or in duration of stay in the intensive care unit (ICU). In all patients, a significant increase in the total white blood cell count, neutrophils, serum IL-6 and C-reactive protein occurred in relation to cardiopulmonary bypass. This was not influenced by heparin precoating of the circuit. In addition, there was an increase in the monocyte count during follow-up, and there was a trend towards higher monocyte counts in the patients who were treated with heparin-coated circuits. These results suggest that the addition of a heparin-coated circuit to the intraoperative 'high- dose' aprotinin therapy probably had little influence on the clinical course and on the time-course of the inflammatory parameters of the adult patients undergoing primary coronary surgery with a full heparinization protocol.",
keywords = "Aprotinin, Cardiopulmonary bypass, Heparin coated circuits, Inflammation",
author = "A. Parolari and F. Alamanni and T. Gherli and S. Salis and R. Spirito and F. Foieni and F. Rossi and A. Bertera and P. Oddono and P. Biglioli",
year = "1999",
month = "1",
doi = "10.1016/S0967-2109(98)00016-7",
language = "English",
volume = "7",
pages = "117--127",
journal = "Cardiovascular Surgery",
issn = "0967-2109",
publisher = "Decker Publishing",
number = "1",

}

TY - JOUR

T1 - 'High dose' aprotinin and heparin-coated circuits

T2 - Clinical efficacy and inflammatory response

AU - Parolari, A.

AU - Alamanni, F.

AU - Gherli, T.

AU - Salis, S.

AU - Spirito, R.

AU - Foieni, F.

AU - Rossi, F.

AU - Bertera, A.

AU - Oddono, P.

AU - Biglioli, P.

PY - 1999/1

Y1 - 1999/1

N2 - Heparin-coated cardiopulmonary bypass circuits reduce the inflammatory response to cardiopulmonary bypass circuit, improve biocompatibility and may protect the postoperative hemostasic mechanisms in routine coronary bypass operations. 'High-dose' aprotinin reduces blood-loss, transfusion needs, and re-explorations as a result of bleeding, and may have an additional role in reducing the inflammatory response of the body to cardiopulmonary bypass circuit. It has not been established, however, if the addition of a heparin- coated circuit to the intraoperative administration of 'high dose' aprotinin further reduces the whole-body inflammatory response to cardiopulmonary bypass circuit and improves the postoperative clinical course of the patients who are undergoing coronary surgery. Thirty patients undergoing primary elective coronary artery bypass grafting were studied. All the patients received, intraoperatively, the serine-protease inhibitor aprotinin according to the 'Hammersmith' protocol and full heparin dose. Patients were randomly allocated to be treated either with a circuit completely coated with surface- bound heparin (n = 15) or with an uncoated, but otherwise identical, circuit (n = 15). Differences in the clinical course of the two groups of patients, as well as differences in the behavior of hematological and inflammatory (interleukin-6 (IL-6) and C-reactive protein) factors before, during and after bypass, were analyzed. There were no significant differences between the two groups in terms of bleeding and transfusional requirements, the time spent on a ventilator, or in duration of stay in the intensive care unit (ICU). In all patients, a significant increase in the total white blood cell count, neutrophils, serum IL-6 and C-reactive protein occurred in relation to cardiopulmonary bypass. This was not influenced by heparin precoating of the circuit. In addition, there was an increase in the monocyte count during follow-up, and there was a trend towards higher monocyte counts in the patients who were treated with heparin-coated circuits. These results suggest that the addition of a heparin-coated circuit to the intraoperative 'high- dose' aprotinin therapy probably had little influence on the clinical course and on the time-course of the inflammatory parameters of the adult patients undergoing primary coronary surgery with a full heparinization protocol.

AB - Heparin-coated cardiopulmonary bypass circuits reduce the inflammatory response to cardiopulmonary bypass circuit, improve biocompatibility and may protect the postoperative hemostasic mechanisms in routine coronary bypass operations. 'High-dose' aprotinin reduces blood-loss, transfusion needs, and re-explorations as a result of bleeding, and may have an additional role in reducing the inflammatory response of the body to cardiopulmonary bypass circuit. It has not been established, however, if the addition of a heparin- coated circuit to the intraoperative administration of 'high dose' aprotinin further reduces the whole-body inflammatory response to cardiopulmonary bypass circuit and improves the postoperative clinical course of the patients who are undergoing coronary surgery. Thirty patients undergoing primary elective coronary artery bypass grafting were studied. All the patients received, intraoperatively, the serine-protease inhibitor aprotinin according to the 'Hammersmith' protocol and full heparin dose. Patients were randomly allocated to be treated either with a circuit completely coated with surface- bound heparin (n = 15) or with an uncoated, but otherwise identical, circuit (n = 15). Differences in the clinical course of the two groups of patients, as well as differences in the behavior of hematological and inflammatory (interleukin-6 (IL-6) and C-reactive protein) factors before, during and after bypass, were analyzed. There were no significant differences between the two groups in terms of bleeding and transfusional requirements, the time spent on a ventilator, or in duration of stay in the intensive care unit (ICU). In all patients, a significant increase in the total white blood cell count, neutrophils, serum IL-6 and C-reactive protein occurred in relation to cardiopulmonary bypass. This was not influenced by heparin precoating of the circuit. In addition, there was an increase in the monocyte count during follow-up, and there was a trend towards higher monocyte counts in the patients who were treated with heparin-coated circuits. These results suggest that the addition of a heparin-coated circuit to the intraoperative 'high- dose' aprotinin therapy probably had little influence on the clinical course and on the time-course of the inflammatory parameters of the adult patients undergoing primary coronary surgery with a full heparinization protocol.

KW - Aprotinin

KW - Cardiopulmonary bypass

KW - Heparin coated circuits

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=0032935513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032935513&partnerID=8YFLogxK

U2 - 10.1016/S0967-2109(98)00016-7

DO - 10.1016/S0967-2109(98)00016-7

M3 - Article

C2 - 10073771

AN - SCOPUS:0032935513

VL - 7

SP - 117

EP - 127

JO - Cardiovascular Surgery

JF - Cardiovascular Surgery

SN - 0967-2109

IS - 1

ER -